CCR5 Antibody (YA5578)
(Synonyms: C-C chemokine receptor type 5; C-C CKR-5; CC-CKR-5; CCR-5; CCR5; CHEMR13; HIV-1 fusion coreceptor; CD antigen CD195; )CCR5 Antibody (YA5578) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CCR5.
-
Host:
Mouse
-
Isotype:
IgG
-
Application:
FC, ELISA
-
Reactivity :
Human
-
Formulation:
Supplied in Phosphate-buffered solution
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
FC
FC: Flow Cytometry
|
|---|---|---|
| Dilution Ratio | 1:5000-100000 | 1-2μg/Test |
Product Details
CCR5 Antibody (YA5578) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CCR5.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 40 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
Purified recombinant human CCR5
affinity purified.
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in Phosphate-buffered solution
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
CCR5 is a human CC chemokine receptor and G protein-coupled receptor that responds to chemokines including RANTES/CCL5, MIP-1α/CCL3, and MIP-1β/CCL4[1]. Mechanistically, ligand-bound CCR5 couples to Gᵢ1 and supports chemokine recognition, receptor activation, immune surveillance, and inflammation[2]. In HIV research models, CCR5 functions as the principal cofactor for entry mediated by envelope glycoproteins of primary macrophage-tropic HIV-1 strains[3]. CCR5, when coexpressed with CD4, enables infection by most primary HIV-1 isolates, whereas CCR3 supports only a more restricted subset, defining an experimentally important distinction from related chemokine receptors[4]. A homozygous CCR5 defect was identified in some multiply exposed individuals resistant to HIV-1 infection, linking receptor expression to viral-entry susceptibility[5]. Compared with related isoforms CCR1 and CCR3, natural LD78β/MIP-1α isoforms show diverging binding capacities that affect CCR5-linked anti-HIV activity and CCR1/CCR3-linked chemotactic responses. For inhibitor studies, maraviroc-bound CCR5 reveals a ligand-binding site distinct from chemokine and gp120 recognition sites, supporting allosteric inhibition of chemokine signaling and viral entry[6]. Maraviroc is a CCR5 antagonist used to block gp120 interaction with CCR5 in HIV/AIDS research and treatment contexts[7].
-
Subcellular Localization
Cell membrane; Multi-pass membrane protein
-
Expression
Tissue_specificity:It is highly expressed in the spleen, thymus, myeloid cell line THP-1, promyelocytic cell line KG-1a, and CD4+ and CD8+ T cells. Its expression level is moderate in peripheral blood leukocytes and the small intestine. Its expression level is low in the ovary and lung.
Induction: (Microbial infection) May be down-regulated by human cytomegalovirus/HHV-5 protein UL78 -
Subunit
Interacts with PRAF2 (PubMed:15757671). Efficient ligand binding to CCL3/MIP-1alpha and CCL4/MIP-1beta requires sulfation, O-glycosylation and sialic acid modifications. Glycosylation on Ser-6 is required for efficient binding of CCL4 (PubMed:10383387, PubMed:11733580, PubMed:8663314, PubMed:8699119). Interacts with GRK2 (PubMed:10085131). Interacts with ARRB1 and ARRB2 (PubMed:11448957, PubMed:16144840). Interacts with CNIH4 (PubMed:24405750). Interacts with S100A4; this interaction stimulates T-lymphocyte chemotaxis (PubMed:30713770)
-
SwissProt ID
-
Synonyms
C-C chemokine receptor type 5; C-C CKR-5; CC-CKR-5; CCR-5; CCR5; CHEMR13; HIV-1 fusion coreceptor; CD antigen CD195;
Documentation
References
[1]. Samson M, et al. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry. 1996 Mar 19;35(11):3362-7. [Content Brief]
[2]. Zhang H, et al. Structural basis for chemokine recognition and receptor activation of chemokine receptor CCR5. Nat Commun. 2021 Jul 6;12(1):4151. [Content Brief]
[3]. Deng H, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996 Jun 20;381(6584):661-6. [Content Brief]
[4]. Choe H, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996 Jun 28;85(7):1135-48. [Content Brief]
[5]. Liu R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996 Aug 9;86(3):367-77. [Content Brief]
[6]. Tan Q, et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science. 2013 Sep 20;341(6152):1387-90. [Content Brief]
[7]. Xu GG, et al. Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications. Curr Top Med Chem. 2014;14(13):1504-14. [Content Brief]
Powered by Bioz
